PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “NEURAMINIDASE”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 919 records · Page 51Linked to original sources

[Role of intracellular proteinases and glycosidases in the degradation of the 'large glycoprotein' responsible for the neuraminidase and hemagglutinating activity of the Newcastle disease virus].

It was shown that the decrease in neuraminidase and hemagglutinin activities in Newcastle disease virus (NDV) infected cells, which was revealed in conditions of disturbed protein synthesis, could be significantly diminished by addition of an inhibitor or trypsin-like proteinases tosyl-lysil-chloromethyl keton. The same effect was caused by D-galactonolactone--inhibitor of some glycosidases. These data suggested that the action of intracellular proteinases and glycosidases are the cause of degradation of 'large glycoprotein', responsible for neuraminidase and hemagglutinin activities in NDV-infected cells.

Animals↗

Neuraminidase inhibitors for treatment of influenza A and B infections.

Influenza epidemics are responsible for an average of approximately 20,000 deaths per year in the United States. The main method for preventing influenza and its severe complications is influenza vaccination. Influenza-specific antiviral drugs are an important adjunct to vaccine but are not a substitute for vaccine. In the United States, four antiviral agents are approved for preventing or treating influenza: amantadine, rimantadine, zanamivir, and oseltamivir. Amantadine was approved for prophylaxis of influenza A(H2N2) infection in the United States in 1966 and was approved for prophylaxis and treatment of influenza A infection in 1976; rimantadine was approved for treatment and prophylaxis of influenza A infection in 1993 [corrected]. This report provides information on two neuraminidase inhibitors, zanamivir and oseltamivir, which were approved in 1999. Neuraminidase inhibitors are a new class of antiviral drugs that inhibit influenza A and B viruses. Zanamivir is approved for treatment of uncomplicated acute illness caused by influenza virus in persons aged > or =12 years who have been symptomatic for no more than 2 days. Oseltamivir is approved for treatment of uncomplicated illness caused by influenza infection in adults aged > or =18 years who have been symptomatic for no more than 2 days. Neither zanamivir nor oseltamivir is approved for influenza prophylaxis. This report and the Advisory Committee on Immunization Practices (ACIP) 1999 recommendations on influenza prevention and control (MMWR 1999;48[No.RR-4]:1-28) can be accessed at the website for the Influenza Branch, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, CDC, at or at the MMWR website at .

Acetamides↗

[Effect of neuraminidase and proteolytic enzymes on electrophoretic mobility of erythrocytes and their aggregation induced by La(3+)].

The effect of neuraminidase, trypsin and pronase on the electrophoretic mobility of human erythrocytes and their aggregation induced by La3+ was studied in vitro. The aggregation of intact red cells differs from that of cells treated with neuraminidase and proteolytic enzymes. The above differences are observed in the range of La3+ suspension concentration from 20 to 330 microM. A possible mechanism of aggregation is discussed.

Cell Aggregation↗

Determination of influenzavirus neuraminidase inhibition titres.

Representatives of the WHO influenza programme recently proposed a standard method of determining neuraminidase activity and neuraminidase inhibition (NI) antibody titres. Logit transformation of the data obtained with the WHO method for the NI assay permits a more efficient performance of the test and easy calculation of titres with a computer programme.

Antibodies↗

Metabolism of the influenza neuraminidase inhibitor prodrug oseltamivir in the rat.

The metabolism of [2-acetyl-(14)C]oseltamivir (GS4104, Ro 64-0796), the prodrug of the novel influenza neuraminidase inhibitor GS4071 (Ro 64-0802), was examined in rats after oral dosing. Intact oseltamivir was observed only in lung and urine, accounting for 37 and 15% of the total radioactivity in these samples, respectively. GS4071 was the major metabolite in plasma, tissues, and urine, and accounted for 32 to 56% of the radioactivity present in these samples. The second most abundant peak in these samples (13-24% of radioactivity) was a novel metabolite (M3). This metabolite was purified from urine of rats dosed orally with oseltamivir and was identified by liquid chromatography-mass spectrometry and NMR as the (R)-omega-carboxylic acid metabolite of oseltamivir. The omega-carboxylic acid metabolite of oseltamivir could not be produced in vitro. However, omega-hydroxylated products of oseltamivir were produced by rat liver microsomes. Both the (R)- and (S)-omega-hydroxylated products were observed, but formation of the (R)-isomer predominated. These data indicated that in the rat, oseltamivir was primarily metabolized to the active influenza neuraminidase inhibitor GS4071 and, to a lesser extent, to an (R)-omega-carboxylic acid metabolite.

Acetamides↗

Influence of neuraminidase on the characteristics of microrheology of red blood cells.

Surface charge was removed from RBC (erythrocyte) membrane to different degrees with biochemical methods, i.e., treatment of RBCs with neuraminidase, either using different doses for the same incubation time (1 hour) or using the same dose (75 milli-unit) for different incubation time. Several rheological properties of the RBCs with surface charge removal were observed, including the deformation index DI (using traditional ektacytometry) orientation index (DI)or and small deformation index (Dl)d (using new ektacytometry), the viscosity at low and high shear rates (using a cone-plate rotating viscosimeter). In addition, photographs of RBCs aggregation under a microscope and the histograms of RBC aggregate size after treatment with neuraminidase were obtained. It is found from these experiments that the decrease of the surface charge of RBCs leads to the decrease in the deformation and orientation indices as well as the increase in blood viscosity.

Animals↗

Neuraminidase inhibitors: progress in the management of influenza.

Influenza is a serious respiratory illness and represents a significant clinical burden. As well as being debilitating, influenza can often cause complications leading to hospitalisation and death. Prophylaxis by vaccination is the preferred method of disease management, but because influenza viruses are constantly changing their antigenic properties, influenza outbreaks occur regularly as epidemics. Neuraminidase inhibitors are a new class of anti-influenza drugs designed to block influenza virus replication. Two neuraminidase inhibitors, zanamivir and oseltamivir, have been licensed for clinical use in the treatment of influenza. Both drugs significantly reduce the severity and duration of the illness when treatment is started within two days of the onset of symptoms. However, while zanamivir and oseltamivir have apparently similar efficacy, they differ in their modes of delivery and tolerability. Zanamivir is delivered direct to the lungs by inhalation and is well tolerated. Oseltamivir is taken in the form of a pill but has the side-effect of producing nausea and vomiting in some patients. In the absence of a demonstrable difference in efficacy, uptake of the two drugs will depend on evaluation of the relative merits of mode of delivery and tolerability.

Acetamides↗

[The rapid detection kit based on neuraminidase activity of influenza virus].

The ZstatFlu test(ZymeTx, USA) is a rapid detection kit for influenza types A and B virus. This test is based upon the reaction between viral neuraminidase from influenza viruses and chromogenic substrate. The positive specimen of influenza type A or B virus cleave the substrate and produce a blue colored product. The ZstatFlu was evaluated by a prototype viruses, isolated viruses and clinical specimens. At result, this kit was reactive for all human influenza type A and B virus. No cross reactivity was detected with other respiratory viruses, including parainfluenza type 1, 2, 3 and mumps viruses with neuraminidase activity. Throat swabs were used for the test. By comparison with cell culture and RT-PCR. The sensitivity and the specificity was 77.0% and 90.2% respectively. The ZstatFlu should be useful for the rapid diagnosis of influenza virus infection.

Humans↗

Contribution to the standardization of influenza neuraminidase inhibition tests, based on enzyme- antienzyme kinetic studies.

1. From enzyme-antienzyme kinetic studies a method for the determination of anti-n2-neuraminidase antibodies has been developed. This procedure is applicable in routine diagnosis. 2. Considering the present conditions, the reversibility of the virus neuraminidase antigen-antineuraminidase antibody complex has been proved. The inhibition must be described as a non-competitive one. 3. As a reference value for comparative immunity estimations the relative antibody concentration T150 is defined as the point of reciprocal serum dilution, where under a given substrate concentration the inhibited enzyme activity vi is half of the non-inhibited enzyme activity vo. 4. For the calculation of T150 a simple formula is derived from the Michaelis-Menten kinetic. Under present conditions the value of T150 is in a range of 1.5 log 2 dilution steps plus or minus the specific serum dilution T150 uninfluenced by possible variable parameters such as enzyme activity, substrate concentration and inhibitor concentration.

Antibodies↗

[Expression of a cloned hemagglutinin-neuraminidase gene from Newcastle disease virus in murine myeloma cells].

Vaccination with autologous cancer cells expressing a potent foreign antigen is promising for immunotherapy of tumors. A construct was obtained to transfect cancer cells with the hemagglutinin-neuraminidase (HN) gene of the Newcastle disease virus (NDV). Specific primers were designed, and the HN cDNA was amplified from RNA isolated from the allantoid fluid of NDV-infected embryonated chicken eggs. The amplified fragment was cloned in pCR2.1, sequenced, and recloned in expression vector pCDNA3.1/Zeo(+). The resulting construct was used to transfect mouse myeloma cells SP2/0. Production of HN was checked by ELISA and by a neuraminidase activity assay. Cell agglutination on ice was proposed as a test for surface HN.

Animals↗

Cytolysis of neuraminidase-treated autochthonous lymphoid cells by autologous serum.

Rabbit lymph node cells treated with bacterial neuraminidase become susceptible to cytolysis by autologous antibody and complement. Cytolysis of cells can be prevented by absorbing out the antibodies, probably IgM antibodies, from the autologous serum using neuraminidase-treated autochthonous lymph node cells. The significance of this mechanism is discussed.

Absorption↗

[Specific resistance and electrophoretic mobility of regenerating liver cells. Effect of ribonuclease and neuraminidase].

Changes of specific resistance and electrophoretic mobility of the cells from regenerative liver of rats are investigated. It is shown that specific resistance decreases and electrophoretic mobility increases during 30 h after hepathectomy. Exogenous ribonuclease decreases electrophoretic mobility by 10% and does not reduce significantly specific resistance. Neuraminidase treatment caused a marked increase (approximately 40%) of specific resistance without reduction in the mobility of cells from both intact and regenerative liver. It is concluded that there is no difference in the sensitivity of the cell surface of normal and regenerative liver to ribonuclease and neuraminidase.

Animals↗

The impact of neuraminidase on apoptosis in cultures of blood lymphocytes isolated from rats bearing morris hepatoma.

Lymphocytes were obtained by heart-punction from rats bearing Morris hepatoma. In the short term, 18-hour cultures of these lymphocytes exhibited a significantly higher amount of apoptotic cells than lymphocyte cultures from the healthy, control animals. Neuraminidase, injected into the caudal vein of the rats with Morris hepatoma, caused a marked lowering in the amount of apoptotic blood-lymphocytes and an elevation of the amount of viable cells. The possible mechanism of neuraminidase preventing the apoptosis of blood-circulating lymphocytes in tumour hosts is discussed herein.

Animals↗

Reduction in the adherence of Pseudomonas aeruginosa to human buccal epithelial cells with neuraminidase inhibition.

The aim of this study was to evaluate the reduction in the adherence of 33 strains of Pseudomonas aeruginosa isolated from humans and different animals to human buccal epithelial cells with neuraminidase inhibition. Buccal epithelial cells were incubated with strains of Pseudomonas aeruginosa in the presence or absence of the neuraminidase inhibitors, 2,3-dehydro-2-deoxy-N-acetyl-neuraminic acid (DANA) or N-acetyl-neuraminic acid (NANA). Incubation of cells with bacteria in the presence of either DANA or NANA reduced bacterial adherence significantly by 35.24 +/- 23.90%, and 68.00 +/- 22.51 %, respectively. We suggest that the in vivo effects of such interventions should be explored as potential mechanisms reducing Pseudomonas aeruginosa in the binding to buccal cells.

Animals↗

[Morphological and functional alterations of ear in lysosomal neuraminidase gene deficient mouse].

OBJECTIVE: To observe the alterations of the auditory function and morphology of the ear in the mouse sialidosis models which has been generated by targeted deletion of lysosomal neuraminidase gene (Neul) and closely resembled the phenotypes in corresponding human conditions, and to explore pathophysiological mechanisms of hearing impairment. METHODS: Neul homozygous (Neul -/-) mice at 3 weeks, 2 and 4 months of age, and their wildtype littermates (Neu1 +/+) were examined for auditory thresholds through auditory brainstem responses (ABR) to click, 8, 16, and 32 kHz stimuli. Morphological analyses in ears were performed by series temporal bone section and light microscopy. RESULTS: Neul -/- mice at 3 weeks of age showed an elevated ABR threshold, 50-55 dB above those of Neul +/+ mice. Up to 2 and 4 months of age, their thresholds were further elevated for 60-68 dB. There were distinct pathological changes of middle and inner ear of 3 weeks of age in Neul -/- mice, especially at 2-4 months of age there were significant cerumen occlusion in the external auditory canal and severe otitis media. Vacuolation associated with lysosomal storage was observed within ossicles and cochlear bone cells, stria vascularis cells, spiral ganglion neurons and macrophages, spiral limbus, spiral prominence, Reissner's membrane cells, and the mesothelial cells of the perilymphatic scala and basilar membrane, but not within the organ of Corti. Vestibular ganglion neurons, hair cells and supporting cells in cristae and maculae also showed vacuolation. CONCLUSIONS: The deficiency of lysosomal neuraminidase may result in a serious hearing loss and morphological alterations of ear. The external auditory canal obstruction, otitis media and ossicle changes may cause conductive hearing loss, and the defects in lysosomal storage of neurons, stria vascularis, spiral limbus, Reissner's membrane and basilar membrane cells may contribute to sensorineural deafness.

Animals↗

[Prolongation of the survival of skin allografts by intravenous injection of neuraminidase-treated donor bone marrow cells in rats].

OBJECTIVE: To optimize the best concentration of neuraminidase (Neu) that enhances the migration of neuraminidase (Neu)-treated donor bone marrow cells (dBMCs) to the liver, and observe the influence of short-term cyclosporin A(CsA) application combined with intravenous injection (i.v.) of Ne treated dBMCs on the survival of skin allografts. METHODS: The experiment consisted of two parts. For selection of an appropriate concentration of Neu, 26 female Wistar rats were randomly divided into four groups. The dBMCs were prepared by routine method and treated with four concentrations (0, 0.5, 1.0, 2.0 U/ml) of Neu at 37 degrees C for 30 min. The untreated and Neu-treated dBMCs were labeled by 99mTc, and injected via the tail veins to female Wistar rats in each group, respectively. After five hours, the radioactivity of various organs collected from sacrificed rats was measured by a gamma counter, and the values were expressed as percentage of total radioactivity of all organs from the same rat. To observe the survival of skin allograft, 23 male Wistar rats were randomly divided into control group, untreated dBMCs group and Neu-treated dBMCs group. All rats in each group were grafted with skin allografts from male Sprague-Dawley (SD) rats. The dBMCs from the same donor without and with Neu treatment by the concentration selected from the above experiment were injected via the tail veins of female Wistar rats in untreated dBMCs group and Neu-treated dBMCs group, respectively. Rats in untreated dBMCs group and Neu-treated dBMCs group received CsA (10 mg/kg) through intraperitoneal injection (i.p.) at 2 and 5 days post-grafting. Neither dBMCs or CsA were given in the control group. The survival of allograft skin in each group was checked and photographed daily after 5 days post operation. RESULTS: When the concentration of Neu was 1.0 U/ml, the percentage of dBMCs in liver was (75.3 +/- 9.8) %, which was obviously higher than that in 0 U/ml group [(58.9 +/- 4.2%)], (P < 0.01), indicating that the optimal concentration of Neu was 1.0 U/ml. The survival time of skin allografts in rats of Neu-treated dBMCs group was prolonged significantly in comparison with that of the rats in dBMCs group without Neu treatment (P < 0.01). The survival time in both dBMCs group and Neu-treated dBMCs group was longer that of control group (P < 0.01), and it was prolonged in Neu-treated dBMCs group compared with that in dBMC group. CONCLUSION: Administration of proper concentration of Neu can increase the affinity of dBMCs to the liver, and promote the Neu-treated dBMCs to migrate to liver. The intravenous injection of Neu-treated dBMCs combined with short-term CsA administration can delay the rejection of skin allografts in rats.

Animals↗

[The determination of neuraminidases in vibrios of the 01 and non-01 groups].

Vibrio cholerae 01 and non 01 neuraminidase may be rapidly detected with the use of a synthetic 4-methylumbelliferyl-neuraminic acid substrate. Other vibrios and Enterobacteriaceae show no neuraminidase activity against this substrate. The method may be used with microorganism cultures grown in solid and liquid nutrient media. The time of analysis is 15-20 min.

Hymecromone↗

Allosteric inhibition of the water-soluble C-terminal fragment of Sendai virus neuraminidase.

Trypsin solubilized hemagglutinin-neuraminidase of Sendai virus (cHN) displays michaelian kinetics, with native fetuin as substrate, at 37 degrees C. Vmax and Km values are only marginally altered, as compared to intact viral neuraminidase. At lower temperatures, cHN follows non-michaelian kinetics, with marked substrate inhibition at 4 degrees C. With denaturated fetuin, michaelian kinetics are observed in all conditions, while asialo fetuin was an uncompetitive inhibitor of cHN, with native fetuin or sialyl lactose as substrates. These results can be explained assuming that the protein moiety of fetuin acts as an allosteric inhibitor of cHN.

Allosteric Site↗